Pharmaceutical and Efficacy study of Ashtadashanga churna in Pulmonary fibrosisrelated with post covid and Post tuberculosis.

Banaras Hindu University0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年11月21日

试验速览

暂无简介。

•1.Patients able to take medicines orally.
•2.Patients willing to provide informed consent shall be included.
•3.Subjects of Post covid-19 will considered upto12 months from the date of RTPCR negative.

•1.Lung fibrosis caused by any other means such as lung cancer, lymphangitis carcinomatosis, bronchiectasis, COPD (chronic obstructive pulmonary diseases),connective tissue disorder, rheumatoid arthritis.
•2.Pulmonary oedema
•3.Subjects with severe vomiting which would make oral administration of medicine difficult.
•4.Pregnant and lactating subjects.
•5.Subjects with severe disease conditions like malignancy and those with advance liver or kidney diseases.
•6.Initially included subjects who during the treatment develops severe other infective diseases or trauma etc.
•7.Active cases of TB and COVID.

发起方